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associated with both treatment failure or toxicity;
• Pharmacodynamic :  may be  divided into 
three subgroups: (1) direct effect at receptor 
function, (2) interference with a biological or 
physiological control process and (3) additive/
opposed pharmacological effect.
In this review, we described the mechanism of 
pharmacokinetic DDI focusing the interest on their 
clinical implications, addressing the reader’s attention 
for pharmaceutical interactions to other original and 
review articles.
METHODS
Medline, PubMed, Embase, Cochrane library and 
Reference lists were searched for articles published 
until June 30 2012, using the words “ADR,” “drug 
interactions,” “polytherapy,” “elderly.”
Pharmacokinetic DDI
Pharmacokinetic interactions are often considered on 
the basis of knowledge of each drug and are identified 
by controlling the patient’s clinical manifestations as 
well as the changes in serum drug concentrations. As 
above reported, they involved all the processes from 
absorption up to excretion that will be now described.
INTRODUCTION
Pharmacovigilance or post‑marketing surveillance aims 
to identify and quantify the risks associated with the 
use of drugs, thus contributing to better understand 
the most important characteristics of adverse drug 
reactions (ADRs) and the pathogenic mechanisms 
involved.[1] Indeed, ADRs represent a common clinical 
problem and can be responsible for an increased number 
and/or duration of hospitalizations.[2,3]
Drug‑drug interactions (DDIs) are one of the 
commonest causes of ADRs and we reported that 
these manifestations are commons in the elderly due 
to poly‑therapy.[4‑7] In fact, poly‑therapy increases the 
complexity of therapeutic management and thereby the 
risk of clinically relevant drug interactions, which can 
induce the development of ADRs, and both reduce,[8,9] 
or increase the clinical efficacy.[10,11]
Poly‑therapy may determine the “prescribing cascade,” 
which occurs when an ADR is misunderstood and 
new potentially unnecessary drugs are administered; 
therefore the patient is at risk to develop further ADRs.[12]
DDI can be classify into two main groups:
• Pharmacokinetic: Involves absorption, distribution, 
metabolism and excretion, all of them being 
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Absorption
Gastro‑intestinal absorption
The complexity of the gastro‑intestinal tract, and the effects 
of several drugs with functional activity on the digestive 
system, represent favourable conditions for the emergence 
of DDI that may alter the drug bioavailability.[13]
Several factors may influence the absorption of a drug 
through the gastrointestinal mucosa. The first factor is 
the change in gastric pH. The majority of drugs orally 
administered requires, to be dissolved and absorbed, a 
gastric pH between 2.5 and 3. Therefore, drugs able to 
increase gastric pH (i.e., antacids, anticholinergics, proton 
pump inhibitors [PPI] or H2‑antagonists) can change the 
kinetics of other co‑administered drugs.
I n  f a c t ,  H 2  a n t a g o n i s t s  ( e . g . ,  r a n i t i d i n e ) , 
antacids (e.g., aluminium hydroxide and sodium 
bicarbonate) and PPI (e.g., omeprazole, esomeprazole, 
pantoprazole) that increase the gastric pH lead to a decrease 
in cefpodoxime bioavailability, but on the other hand, 
facilitate the absorption of beta‑blockers and tolbutamide.
Moreover, antifungal agents (e.g., ketoconazole or 
itraconazole), requires an acidic environment for being 
properly dissolved, therefore, their co‑administration with 
drugs able to increase gastric pH, may cause a decrease 
in both dissolution and absorption of antifungal drugs.[14] 
Therefore, antacid or anticholinergics, or PPI might be 
administered at least 2 h after the administration of 
antifungal agents.[15]
Similarly, the administration of drugs able to increase 
the gastric pH (see above) with ampicillin, atazanavir, 
clopidogrel, diazepam, methotrexate, vitamin B12, 
paroxetine and raltegravir are not recommended.
In contrast, the ingestion of drugs that cause a decrease in 
gastric pH (e.g., pentagastrin), may have an opposite effect. 
It is worth noting that severity of DDIs caused by alteration 
of gastric pH mainly depends on pharmacodynamics 
characteristics of the involved drug, in terms of narrow 
therapeutic range.
Another factor that modifies the drug absorption 
i s  the  format ion  o f  complexes .  In  th i s  case , 
tetracyclines (e.g., doxycycline or minocycline) in the 
digestive tract can combine with metal ions (e.g., calcium, 
magnesium, aluminum, iron) to form complexes poorly 
absorbed. Consequently certain drugs (e.g., antacids, 
preparations containing magnesium salts, aluminum and 
calcium preparations containing iron) can significantly reduce 
the tetracyclines absorption.[16] Analogously, antacids reduce 
the absorption of fluoroquinolones (e.g., ciprofloxacin), 
penicillamines and tetracyclines, because the metal ions 
form complexes with the drug. In agreement, was observed 
that antacids and fluoroquinolones should be administered 
at least 2 h apart or more.[17,18]
Cholestyramine and colestipol bind bile acids and prevent 
their absorption in the digestive tract,[19] but they can also bind 
other drugs, especially acidic drugs (e.g., warfarin, acetyl 
salicylic acid, sulfonamides, phenytoin, and furosemide). 
Therefore, the interval between the administration of 
cholestyramine or colestipol and other drugs may be as 
long as possible (preferably 4 h).[20]
Motility disorders represent the third factor involved 
in absorption DDIs. Drugs able to increase the gastric 
transit (e.g., metoclopramide, cisapride or cathartic) can reduce 
the time of contact between drug and mucosal area of absorption 
inducing a decrease of drug absorption (e.g., controlled‑release 
preparations or entero‑protected drugs).[21]
For example, metoclopramide, may accelerate gastric 
emptying, hence decreasing the absorption of digoxin and 
theophylline whereas it can accelerate the absorption of 
alcohol, acetylsalicylic acid, acetaminophen, tetracycline 
and levo‑dopa.[22]
Finally, iron can inhibits the absorption of levodopa and 
metildopa.
Modulation of P‑glycoprotein (P‑gp) intestinal
P‑gp or gp‑120 for its molecular weight, is a transmembrane 
protein encoded by the human multidrug resistance 
gene‑1 belonging to the adenosine triphosphate‑binding 
cassette (ABC) superfamily, together with other 41 
members grouped in 7 families (A to G).[23] Localized in 
liver, pancreas, kidney, small and large intestine, adrenal 
cortex, testes and leukocytes, P‑gp plays a protective role 
influencing the trans membrane drugs diffusion thus 
reducing their absorption or increasing their excretion 
or limiting their tissues distribution (i.e., central nervous 
system, foetal and gonadic tissues).[24]
P‑gp regulates the intestinal absorption of drugs (it is present 
on the luminal surface of enterocytes) and promotes their 
excretion (it is present on the side tubular of epithelium 
renal and biliary side of hepatocytes). Therefore, the 
administration of drugs able to stimulate to inhibit the 
activity of P‑gp, can induce the development of DDI.
The P‑gp inhibition can significantly increase the 
bioavailability of drugs poorly absorbed.[25]
Among the interactions studied at the time of this 
review, it is worth mentioning the effects of terfenadine 
Caterina, et al.: Pharmacokinetic drug‑drug interaction
Journal of Research in Medical Sciences| July 2013 | 602
on the transport of doxorobucin as well as the effects 
chlorpromazine and progesterone on the transport 
of cyclosporine.[26] The DDIs on P‑gp might induce a 
clinical effect in presence of drugs with a low therapeutic 
index (e.g., digoxin, theophylline, anticancer drugs) when 
co‑administered with macrolides (e.g., erythromycin, 
roxithromycin, clarithromycin), PPIs (e.g., omeprazole or 
esomeprazole) or anti‑arrhythmic drugs (e.g., dronaderon, 
amiodarone, verapamil or diltiazem).
Many drugs (but not all) that are transported by P‑gp 
are also metabolized by cytochrome P450 (CYP) isoform 
3A4 (e.g., cyclosporine, antiepileptic drugs, antidepressant, 
fluoroquinolones, quinidine and ranitidine), which can 
confound interpretation of interactions (see later).
Therefore, the co‑administration of these drugs with known 
inhibitors of P‑gp above described results in a clinically 
evident DDI.
Recently, it has been described that aripiprazole and its 
active metabolite, dehydroaripiprazole, but no risperidone, 
paliperidone, olanzapine and ziprasidone are strong P‑gp 
inhibitors, in vitro, while in vivo their administration is 
unlikely to induce DDIs at the blood‑brain‑barrier, but the 
possibility of DDIs in the intestine cannot be neglected.
However, it is important to underline that a DDI could 
be also used in clinical management. In fact, Shi et al.[27] 
documented that sildenafil inhibits the transporter function 
of P‑gp, suggesting a possible strategy to enhance the 
distribution and potentially the activity of anticancer drugs.
DISTRIBUTION
Usually, drugs are transported through a binding to 
plasma and tissues proteins. Of the many plasma proteins 
interacting with drugs, the most important are albumin, 
α1‑acid glycoprotein, and lipoproteins. Acidic drugs are 
usually bound more extensively to albumin, while basic 
drugs are usually bound more extensively to α1‑acid 
glycoprotein, lipoproteins, or both. Only unbound drug 
is available for passive diffusion to extravascular or tissue 
sites and typically determines drug concentration at the 
active site and thus its efficacy. Albumin represents the 
most prominent protein in plasma, it is synthesized in 
the liver and distributed in both plasma and extracellular 
fluids of skin, muscles and various tissues. Intestinal fluid 
albumin concentration is about 60% of that in the plasma. 
Since albumin has five binding sites (i.e., for warfarin, 
benzodiazepines, digoxin, bilirubin and tomoxifen), the 
main characterized are the site I and II.[28]
Site I, also known as the warfarin binding site, is formed 
by a pocket in subdomain IIA,[29] while site II located in 
subdomain IIIA is known as the benzodiazepine‑binding 
site. Ibuprofen and diazepam are selective drug probes for 
site II.[29‑31] [Table 1]
As the free molecules interact with their molecular 
targets and are metabolized, other molecules come into 
solution to reach the site of action. The degree of plasma 
protein binding, expressed by the ratio of bound drug 
concentration/free drug concentration, varies greatly 
among drugs, possibly reaching very high values, especially 
when it is greater than 0.9, otherwise it is considered to be 
low (<0.2). Drugs that have a high degree of plasma protein 
binding are potentially more likely to be displaced by 
drug with greater affinity for the same binding site. From 
a mere clinical point of view, that displacement could be 
associated with symptoms, side effects or toxicities when 
the displaced drug has a higher degree of binding to plasma 
proteins (>90%), reduced volume of distribution, narrow 
therapeutic index, and it is characterized by a faster onset 
of the effect
A typical pharmacological displacement can be observed 
when warfarin and diclofenac are co‑administered. Warfarin 
and diclofenac have same affinity for albumin, therefore the 
administration of diclofenac to a patient treated chronically 
with warfarin results in displacement of latter from its 
binding site. The increase in plasma concentration of free 
warfarin causes the development of serious hemorrhagic 
reactions.
Metabolism
The CYP enzyme family plays a dominant role in the 
biotransformation of a wide number of drugs. In man, 
there are about 30 CYP isoforms, which are responsible 
for drug metabolism and these belong to families 1‑4, 
but only 6 out of 30 isoforms belonging to families CYP1, 
2 and 3 (i.e., CYP1A2, 3A4, 2C9, 2C19, 2D6 and 2E1) are 
mainly involved in the hepatic drug metabolism.[32‑35]
Table 1: Drugs binding to site I (warfarin) or II 
(benzodiazepines) of albumin
Site I (warfarin) Site II (benzodiazepines)
Chlorothiazide Ketoprofen
Phenytoin Ibuprofen
Glibenclamide Indomethacin
Naproxen Dicloxacilline
Salicylates Nimesulide
Nimesulide
Diclofenac
Sulphamidics
Fluoroquinolones
Valproate
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The broad range of drugs that undergo CYP mediated 
oxidative biotransformation is responsible for the large 
number of clinically significant drug interactions during 
multiple drug therapy. Many DDIs are related to the 
inhibition or induction of CYP enzymes.
Inhibition
Inhibition‑based DDIs constitute the major proportion of 
clinically relevant DDIs. In this process enzyme activity is 
reduced due to direct interaction with a drug, usually begins 
with the first dose of the inhibitor, while the extinction of 
inhibition is related to the drug half‑lives.[36,37]
The metabolic inhibition may be reversible (competitive, 
metabolic‑intermediate complex, non‑competitive) or 
irreversible, and clinical effects are influenced by basic 
mechanisms.
Reversible inhibition
Competitive
The competitive inhibition occurs when inhibitor and 
substrate compete for the same binding site on the enzyme. 
In this type of interaction, the inhibition mechanism is direct 
and is rapidly reversible.
The drugs are converted through multiple CYP dependent 
steps to nitroso‑derivatives that bind with high affinity to 
the reduced form of CYP enzymes. Thus CYP enzymes 
are unavailable for further oxidation and synthesis of new 
enzymes is therefore, the only means by, which activity can 
be restored and this may take several days.[38]
It depends on the substrate‑versus‑inhibitor binding 
constant ratio, and on the relative concentrations of each 
species. Some of the inhibitors of CYP3A4 that act by this 
mechanism of inhibition include azole antifungal agents, 
some HIV protease inhibitors such as nelfinavir mesylate,[39] 
and antihypertensives such as diltiazem.[40] In particular, it 
has been reported a two‑fold decrease in oral clearance of 
metoprolol in presence of propafenone; therefore, during 
a co‑administration the dose of metoprolol should be 
reduced.[41]
However, recently we reported a case of an 85‑year‑old 
woman that developed visual hallucinations and 
psychomotor agitation during the treatment with 
venlafaxine and propafenone.[42] We postulated a DDI 
between venlafaxine and propafenone because venlafaxine 
is metabolized primarily by CYP2D6 and is a substrate of 
P‑gp, while propafenone is a known substrate and inhibitor 
of both CYP2D6 and P‑gp. Therefore, propafenone may be 
induced an increase of venlafaxine plasma concentrations 
with the development of hallucinations.
Similar DDI are seen in the combined administration of 
thioridazine and propranolol (CYP2D6),[43] fluoxetine 
and desipramine (CYP2D6),[44] omeprazole and diazepam 
(CYP2C19),[45‑47] tolbutamide and phenytoin (CYP2C9),[48] 
and diltiazem and cyclosporin (CYP3A).[49‑51]
Omeprazole, a CYP2C19 inhibitor, decreases the antiplatelet 
activity of clopidogrel by inhibiting the biotransformation 
of the clopidogrel pro drug into its active metabolite.[52] 
In patients hospitalized for acute coronary syndrome, 
this interaction is associated with a 27% increased risk 
of death or re‑hospitalization.[53] By analogy, inhibition 
of CYP2C19 by etravirine may also inhibit clopidogrel 
antiplatelet activity. Until more data become available, the 
co‑administration of CYP2C19 inhibitors (e.g., etravirine 
and omeprazole) and clopidogrel is not recommended.
Moreover, omeprazole treatment should be well evaluated 
in elderly patients due the possibility to induce the 
development of ADR. In fact, previously we reported in an 
elderly man the development of delirium probably related 
to a DDI between omeprazole and amitriptyline through 
the CYP2C19 inhibition.[54]
Amiodarone is metabolized by CYP3A4 and 2C8; in vitro 
is an inhibitor of CYP3A4, 1A2, 2C9 and 2D6. Due to its 
long half‑life (about 30 days), the risk of interaction must 
be extended also at the period after the treatment with 
amiodarone. However, the risk of interactions may also 
depend on its main metabolite, desethylamiodarone, a 
competitive inhibitor of CYP2D6, an irreversible inhibitor 
of CYP2A6, 3A4, and 2B6 (for formation of covalent bond), 
a mixed inhibitor of CYP1A1, 1A2, 2C9 and 2C19.[55]
Similarly, HIV protease inhibitors (i.e., saquinavir and 
ritonavir) increase sildenafil serum concentrations up to 
11‑fold.[56] Similarly, it has been recently reported that 
azole antifungal drugs (i.e., ketoconazole, itraconazole, 
voriconazole and posaconazole) are CYP3A inhibitors 
able to induce DDIs.[57] In particular posaconazole exhibit 
inhibitory effects upon CYP3A and PGP and at the dosage 
of 200 mg for 10 days can able to reduce from 1.2 to 1.5 
fold the steady‑state clearance of cyclosporine. Moreover, 
in an open‑label study performed in 36 healthy volunteers, 
the treatment with posaconazole (400 mg twice daily) for 
14 days increased the plasma concentrations of tacrolimus of 
2.2‑fold, the area under the curve (AUC) of 4.5‑fold, and the 
half‑life up to 7.5 h.[58] Therefore, the dosage of tacrolimus 
should be reduced up to 66% of the original dose, in presence 
of posaconazole. Similar DDI have been documented when 
azole antifungal treatment was administered in patients 
taking sirolimus or everolimus, therefore, an empiric dose 
reductions of 50% may be considered for both sirolimus 
and everolimus.
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However, in a single‑centre study enrolling 20 healthy 
subjects, Kapil et al.,[59] documented the lack of a clinically 
significant CYP3A4 interaction between ketoconazole and 
transdermal delivery of buprenorphine. It is consistent 
with the parenteral administration of a high clearance 
drug bypassing exposure to gut wall and hepatic CYP3A4 
first‑pass effects.
Metabolic‑intermediate complexes
The production of metabolic‑intermediate complexes is 
an unusual form of inibition where the inhibitor binds 
only to the enzyme‑substrate complex. The formation of a 
metabolic‑intermediate complexes results from inhibitors that 
have an N‑alkyl substituent. After the binding of inhibitor, the 
latter is oxidized by 3A4 and the resultant oxidized species 
of the inhibitor remains complexed with the reduced heme 
group of CYP3A4 forming a complex slowly reversible. 
Erythromycin is a well‑known CYP3A4 inhibitors that use this 
mechanism of inhibition,[60] whereas clarythromycin display 
reduced inhibitory effects with a good clinical efficacy.[61]
Non‑competitive
In the non‑competitive mechanism, the inhibitor and 
substrate do not compete for the same active site, because 
the presence of an allosteric site. Once a ligand binds the 
allosteric site the conformation of the active site changes, 
its ability to bind the substrate decreases and the product 
formation tails off. Many drugs are non‑competitive 
inhibitors of CYP isoforms, as well as omeprazole and 
lansoprazole, and cimetidine.[62,63] The duration of this type 
of inhibition may be longer if new enzymes have to be 
synthesized after the inhibitor drug is discontinued.
Irreversible inhibition
The metabolite resulting from the oxidation of the substrate 
by CYP3A4 becomes irreversible and covalently bound 
to 3A4, thus leading to a permanent inhibition of the 
enzyme. In the case of irreversible inhibition the critical 
factor is represented by the total amount rather than the 
concentration of the inhibitor to which CYP isoenzyme is 
exposed. Lipophilic and large molecular size drugs are more 
likely to cause inhibition.[25] Two characteristics make a drug 
susceptible to inhibitory interactions: one metabolite must 
account for >30‑40% metabolism of a drug and that 
metabolic pathway is catalyzed by a single isoenzyme.[48]
Inhibitor will decrease the metabolism of substrate and 
generally lead to increased drug effect or toxicity of the 
substrate. If the drug is a pro drug the effect is decreased.
Garraffo et al. investigated in an open‑label study the 
effects of single‑dose administration and steady‑state 
concentrations of tipranavir 500 mg and ritonavir 200 mg 
combination on the pharmacokinetics of tadalafil 10 mg.[64] 
The authors documented that even if antiretroviral activity 
of both tipranavir and ritonavir may not be reduced, 
the dose of tadalafil should be reduced at the start of 
antiretroviral therapy and then a full dose can be resumed 
after steady state is reached.
The co‑administration of 3A4 inhibitors with the 
hydroxymethylglutaryl ‑coenzyme A reductase 
inhibitors (statins; e.g., simvastatin) could increase the risk of 
myopathy[65] and rhabdomyolysis.[66] However, it is important 
to understand that during the treatment with statins it is 
possible the development of myopathy also for metabolic 
saturation, in particular during the poly‑therapy.[67]
Metabolic induction
Drug interactions involving enzyme induction are not 
as common as inhibition‑based drug interactions but 
equally profound and clinically important. Exposure to 
environmental pollutants as well as the large number of 
lipophilic drugs can result in induction of CYP enzymes. 
The most common mechanism is transcriptional activation 
leading to increased synthesis of more CYP enzyme 
proteins.[61] The effect of induction is simply to increase the 
amount of P450 present and speed up the oxidation and 
clearance of a drug.[43]
The most commons enzyme inducers are rifampicin,[68‑76] 
phenobarbital,[76,77] phenytoin,[77,78] carbamazepine,[78‑80] and 
anti‑tubercular drugs.[79]
Rifampicin induces CYP3A enzymes in the liver, although 
weak induction of other CYP enzymes, including, CYP2A6, 
CYP2C and CYP2B6, have also been noticed. Rifampicin 
increases the elimination of a large number of drugs, 
although most of them are substrates for CYP3A4, such as 
midazolam, quinidine, cyclosporine A and many steroids.
Metabolism of the affected drug is increased leading to 
decreased intensity and duration of drug effects.[81] It is rather 
difficult to predict the time‑course of enzyme induction because 
of several factors, including the half‑life and the enzyme 
turnover, which determine the time‑course of induction. 
A complicating factor is that the time‑course of induction 
depends on the time required for enzyme degradation and 
new enzyme production.
The short half‑life of rifampicin results in enzyme 
induction (CYP3A4, CYP2C), apparent within 24 h, whereas 
phenobarbital, which has a half‑life of 3‑5 days, requires 
approximately 1 week for induction (CYP3A4, CYP1A2, 
CYP2C) to become apparent. These enzyme‑induction 
reactions also occur with smoking and long‑term alcohol 
or drug consumption and can reduce the duration of action 
of a drug by increasing its metabolic elimination.
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Recently, we documented in a patient with epilepsy a DDI 
between phenobarbital and lamotrigine that induced the 
development of leukopenia and thrombocytopenia. We 
postulated that CYP enzyme induction by phenobarbital 
could be responsible for the production of reactive 
metabolites of lamotrigine that might be causative for the 
observed hematologic effects.[82]
DDIs during excretion
The organs and vehicles  deputy at  the drugs 
excretion (elimination) are kidneys, liver, lungs, feces, 
sweat, saliva, milk. The excretion through saliva, sweat and 
lungs (for volatile drugs) and milk has little quantitative 
significance, but the milk is important when the drugs can 
reach the baby during lactation.
Drugs are excreted mainly through:
• Renal tubular excretion (glomerular filtration, tubular 
reabsorption and active tubular secretion)
• Biliary excretion.[83]
The drugs elimination from the body can undergo many 
interactions being excreted by another drug in this organ 
from, which it is excreted.[84]
The kidney is the organ responsible for the elimination of 
drugs and their metabolites. The interaction may occur for 
a mechanism of competition at the level of active tubular 
secretion, where two or more drugs use the same transport 
system. An example is given by NSAIDs that determine the 
appearance of toxic effects caused by methotrexate when the 
renal excretion of the anti‑proliferative drug is blocked.[85]
It was also demonstrated that amoxicillin decreased the 
renal clearance of methotrexate.[86]
Probenecid, a potent inhibitor of the anionic pathway of 
renal tubular secretion, increases of 2.5 times the area under 
the AUC of oseltamivir.[87]
However, this competition between drugs can be exploited 
for therapeutic purposes. For example, probenecid can 
increase the serum concentration of penicillins and 
cephalosporins, delaying their renal excretion and thus 
saving in terms of dosage. In fact, probenecid acts by 
competitively inhibiting an organic anion transporter 
in renal tubules, thus increasing plasma concentrations 
of other transporter substrates, while reducing their 
excretion.[88]
Several drugs are able to interfere with tubular transport. 
In particular, cimetidine, an H2 receptor inhibitor, may 
influence the tubular secretion of different molecules. Its 
effect on the influx and the efflux of organic cations through 
human organic cation transporter ([hOCT1 and hOCT2] 
and human multidrug and toxin extrusion [hMATE1 and 
hMATE2‑K]) could modify other drug serum concentration 
despite a normal renal function.[89]
Moreover,  in vitro study documented that PPIs 
(i.e., omeprazole, pantoprazole, lansoprazole, rabeprazole, 
and tenatoprazole) are potent hOCT‑inhibitors and 
could modulate the transport of metformin.[90] However, 
the clinical relevance of this DDIs may be clarify. The 
interactions can also occur during tubular reabsorption. 
Many drugs, when they are in an ionized form in the urine, 
pass by diffusion in tubular cells. The changes in urinary pH, 
pharmacologically induced, influence the state of ionization 
of certain drugs and may therefore affect the re‑absorption 
from the renal tubule.[91]
In particular, if the pH of the urine is alkaline the absorption 
of acidic drugs is reduced, while, in the presence of an 
acidic pH, basic drug absorption is reduced.
The changes in urinary pH, however, assume practical 
importance only if the pKa of the drug, i.e., the pH at which 
50% of the molecules in solution is present in ionized form, 
is between 7.5 and 10.5 for the bases, and between 3.0 and 
7.5 for acids.
In fact, the pKa values can cause appreciable changes in 
the degree of dissociation of the drug. Compounds such 
as ammonium chloride, tromethamine and diuretics, being 
able to change urine pH, may affect the excretion of several 
acidic and basic drugs,[15] and this interaction may be used 
to facilitate the removal of drugs from the body. On the 
contrary, the interaction between diuretics and lithium salts 
can still have negative effects on the patient.
Lithium is a monovalent cation whose excretion is 
influenced by changes of serum sodium. Therefore, a high 
excretion of sodium induced by chronic treatment with 
some diuretics such as thiazides, may increase lithium 
re‑absorption, causing serious toxic effects from relative 
over dosage.[92,93]
Some acidic and basic drugs with the high degree of 
ionization are transferred through the epithelium of the 
renal tubule by active transport. The speed transfer of 
molecules depends on the availability of the transporter, 
a protein that allows the transfer through the cellular 
membranes. Therefore, when two drugs are substrate of 
the same transmembrane transporter they can complete 
each other, up to the saturation of transporter capacity. 
At that time, the rate of elimination approaches to a zero 
order (saturable) process.
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Strategy to prevent pharmacokinetic DDI
The Summary of Product Characteristics (SPCs) represents 
the primary source of information about DDIs for health 
care professionals. Unfortunately, DDI cannot be listed 
exhaustively. consequently the information on potential 
DDIs may be insufficiently described, due to the limited 
space in the SPC.
In fact, in an Italian study cross‑sectional study, was found 
that the 3.0% of PPI users were exposed to potential DDI 
within 1 year of follow‑up, according to the risk described in 
the Italian SPCs of PPIs, but this proportion was three‑fold 
higher (9.0%) when information about DDI risk with PPIs, 
reported on Drugdex, was considered.[94]
Therefore, reports on DDI that consider different sources 
updated on the basis of current evidence from the literature 
should be useful to evaluate a possible risk of DDI 
particularly in elderly patients with poly‑therapy.
Moreover, even if not always available and feasible, the 
adoption of therapeutic drug monitoring protocols in 
the above reported patients (i.e., elderly people with 
comorbidities treated with multiple drugs) should be 
considered an important instrument to decrease the 
occurrence and magnitude of DDIs that could induce either 
an increase in health costs for the Health system and a legal 
responsibility for the clinicians.
Therefore, we hope that the National Health System plan a 
strategy intervention to keep physicians adequately aware 
of potential DDI, with particular regard to widely used 
medications.
However, in this time, reports on DDIs that consider different 
sources updated on the basis of current evidence from the 
literature should be useful to evaluate a possible risk of DDI 
particularly in elderly patients with poly‑therapy.
Previously it has been reported that genetic polymorphism of 
CYP enzymes played a significant role in the clinical effects of 
drug treatment[7,95,96] as well as in the development of DDIs.[97]
In this light, even if not always available and feasible, both 
the adoption of therapeutic drug monitoring in patients 
with multiple drug treatment and in vitro techniques to 
predict the role of CYP enzymes polymorphism in DDIs, 
should be considered an important instrument to decrease 
the occurrence and magnitude of DDIs.
CONCLUSIONS
DDIs represent a common clinical problem during the 
management of patients treated with several drugs. 
However, may be underlined that only two drugs are able 
to induce the development of a DDI even if this clinical 
relevance is related to the pharmacology of each drug. In 
fact, a DDI will be able to induce a clinically relevant effect 
in presence of drugs with a low therapeutic index, a long 
half‑life and a higher bound with plasma proteins.
Moreover, it is important to underline that the development 
of DDI is not a problem a class of drug but of a single drug 
and this problem could be under estimated considering 
the SPC only.
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